1.
Munford RS: Statins and the acute-phase response. N Engl J Med 2001;344:2016–2018.
2.
Danesh J, Collins R, Appleby P, Peto R: Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary artery disease. Meta-analysis of prospective studies. JAMA 1998;279:147–1482.
3.
Hoffmeister A, Rothenbacher D, Bäzner U, Frölich, Brenner H, Hombach V, Koenig W: Role of novel markers of inflammation in patients with stable coronary heart disease. Am J Cardiol 2001;87:262–266.
4.
Pasceri V, Willerson JT, Yeh TH: Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation 2000;102:2165–2168.
5.
Zwaka TP, Hombach V, Torzewski J: C-reactive protein-mediated low density lipoprotein uptake by macrophages. Circulation 2001;103:1194–1197.
6.
Albert MA, Danielson E, Rifai N, Ridker PM for the PRINCE Investigators: Effect of statin therapy on C-reactive protein levels. The pravastatin inflammation/CRP evaluation (PRINCE): A randomized trial and cohort study. JAMA 2001;286:64–70.
7.
Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH: Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997;336:973–979.
8.
Levinson SS, Elin RJ: What is C-reactive protein telling us about coronary artery disease? Arch Intern Med 2002;162:389.
9.
Rost NA, Wolf PA, Kase CS, et al: Plasma concentration of C-reactive protein and risk of ischemic stroke and transient ischemic attack. The Framingham Study, Stroke 2001;32:2575.
10.
Zebrack JS, Anderson JL. Maycock CA, et al: Usefulness of high-sensitivity C-reactive protein in predicting long-term risk of death or acute myocardial infarction in patients with unstable or stable angina pectoris or acute myocardial infarction. Am J Cardiol 2002;89:145.
11.
Ridker PM, Hennekens CH, Buring JE, Rifai N: C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000;342:836–843.
12.
Ridker PM, Rifai N, Clearfield M, Downs JR, Weis SE, Miles JS, Gotto AM Jr for the Air Force/Texas Coronary Atherosclerosis Prevention Study Investigation. N Engl J Med 2001;344:1959–1965.
13.
Eidelman RS, Lamas GA, Hennekens CH, Ridker PM: Aspirin, postmenopausal hormones, and C-reactive protein. Arch Intern Med 2002;162:480.
© 2002 S. Karger AG, Basel
2002
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the...
© 2002 S. Karger AG, Basel
2002
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.